Literature DB >> 6123639

Dangerous interaction between amiodarone and quinidine.

R Tartini, L Kappenberger, W Steinbrunn, U A Meyer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6123639     DOI： 10.1016/s0140-6736(82)92400-x

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  17 in total

1.  Which concentration of the inhibitor should be used to predict in vivo drug interactions from in vitro data?

Authors:  Kiyomi Ito; Koji Chiba; Masato Horikawa; Michi Ishigami; Naomi Mizuno; Jun Aoki; Yasumasa Gotoh; Takafumi Iwatsubo; Shin-ichi Kanamitsu; Motohiro Kato; Iichiro Kawahara; Kayoko Niinuma; Akiko Nishino; Norihito Sato; Yuko Tsukamoto; Kaoru Ueda; Tomoo Itoh; Yuichi Sugiyama
Journal:  AAPS PharmSci       Date:  2002

Review 2.  Risk-benefit assessment of amiodarone in the treatment of cardiac arrhythmias.

Authors:  P J Counihan; W J McKenna
Journal:  Drug Saf       Date:  1990 Jul-Aug       Impact factor: 5.606

Review 3.  Amiodarone: the experience of the past decade.

Authors:  W J McKenna; E Rowland; D M Krikler
Journal:  Br Med J (Clin Res Ed)       Date:  1983-12-03

4.  Influence of amiodarone on antipyrine pharmacokinetics in three patients with ventricular tachycardia.

Authors:  C Staiger; R Jauernig; J de Vries; E Weber
Journal:  Br J Clin Pharmacol       Date:  1984-08       Impact factor: 4.335

Review 5.  Pharmacokinetic drug interactions with amiodarone.

Authors:  L J Lesko
Journal:  Clin Pharmacokinet       Date:  1989-08       Impact factor: 6.447

Review 6.  Adverse effects of amiodarone. Pathogenesis, incidence and management.

Authors:  G V Naccarelli; R L Rinkenberger; A H Dougherty; D M Fitzgerald
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Jul-Aug

Review 7.  Antiarrhythmic agents: drug interactions of clinical significance.

Authors:  T C Trujillo; P E Nolan
Journal:  Drug Saf       Date:  2000-12       Impact factor: 5.606

Review 8.  Clinical pharmacokinetics of amiodarone.

Authors:  R Latini; G Tognoni; R E Kates
Journal:  Clin Pharmacokinet       Date:  1984 Mar-Apr       Impact factor: 6.447

Review 9.  QT-interval prolonging drugs: mechanisms and clinical relevance of their arrhythmogenic hazards.

Authors:  M Zehender; S Hohnloser; H Just
Journal:  Cardiovasc Drugs Ther       Date:  1991-04       Impact factor: 3.727

10.  Amiodarone-induced vasculitis and polyserositis.

Authors:  M Stäubli; A Zimmermann; J Bircher
Journal:  Postgrad Med J       Date:  1985-03       Impact factor: 2.401
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.